Pitcairn CO Axsome Therapeutics, Inc. Transaction History

Pitcairn CO

$1.67 Billion
Q3 2024

A detailed history of Pitcairn CO transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Pitcairn CO holds 4,414 shares of AXSM stock, worth $412,753. This represents 0.02% of its overall portfolio holdings.

Number of Shares

4,414

Previous 4,975 11.28%

Holding current value

$412,753

Previous $400,000 1.0%

% of portfolio

0.02%

Previous 0.02%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$78.93 - $95.84 $44,279 - $53,766	-561 Reduced 11.28%	4,414 $396,000
Q2 2024 Aug 13, 2024	BUY	$65.72 - $80.5 $19,781 - $24,230	301 Added 6.44%	4,975 $400,000
Q1 2024 May 13, 2024	SELL	$69.39 - $97.64 $20,123 - $28,315	-290 Reduced 5.84%	4,674 $372,000
Q4 2023 Feb 14, 2024	SELL	$57.42 - $83.61 $7,923 - $11,538	-138 Reduced 2.7%	4,964 $395,000
Q3 2023 Nov 13, 2023	BUY	$69.25 - $82.21 $4,639 - $5,508	67 Added 1.33%	5,102 $356,000
Q2 2023 Aug 11, 2023	SELL	$58.41 - $90.35 $934 - $1,445	-16 Reduced 0.32%	5,035 $361,000
Q1 2023 May 05, 2023	BUY	$58.39 - $75.0 $3,445 - $4,425	59 Added 1.18%	5,051 $311,000
Q4 2022 Feb 13, 2023	BUY	$39.94 - $79.72 $19,890 - $39,700	498 Added 11.08%	4,992 $385,000
Q3 2022 Nov 10, 2022	BUY	$36.06 - $69.85 $162,053 - $313,905	4,494 New	4,494 $201,000
Q4 2021 Feb 14, 2022	SELL	$30.7 - $43.36 $241,731 - $341,416	-7,874 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$19.91 - $68.26 $61,263 - $210,036	3,077 Added 64.14%	7,874 $260,000
Q2 2021 Aug 11, 2021	BUY	$50.63 - $73.5 $16,302 - $23,667	322 Added 7.2%	4,797 $324,000
Q1 2021 May 10, 2021	BUY	$55.91 - $81.44 $250,197 - $364,444	4,475 New	4,475 $253,000

Others Institutions Holding AXSM

# of Institutions

326

Shares Held

37.7M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $4.01B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

News

Stay updated on Pitcairn CO with notifications on news.

Account